Dimensional Fund Advisors LP Has $17.24 Million Holdings in Dyne Therapeutics, Inc. $DYN

Key Points

• Dimensional Fund Advisors increased its Dyne Therapeutics stake by 870.3% in the first quarter, holding 951,589 shares worth approximately $17.24 million. Institutional investors collectively own 96.68% of DYN.
• Insiders have been net sellers recently: insiders sold 1.56 million shares worth $34.39 million over the past 90 days, including a 480,240-share sale by Director Jason P. Rhodes.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and average price target of $34.42 versus the stock’s $26.25 opening price. However, Dyne missed its latest quarterly EPS estimate, reporting a loss of $1.08 per share versus expectations of $0.75.

Dimensional Fund Advisors LP boosted its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 870.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 951,589 shares of the company's stock after buying an additional 853,515 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.58% of Dyne Therapeutics worth $17,244,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of DYN. Fisher Asset Management LLC acquired a new stake in Dyne Therapeutics in the 4th quarter worth approximately $4,891,000. Clearbridge Investments LLC acquired a new stake in Dyne Therapeutics during the fourth quarter valued at approximately $7,976,000. Frazier Life Sciences Management L.P. increased its position in shares of Dyne Therapeutics by 16.0% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,153,082 shares of the company's stock worth $61,674,000 after purchasing an additional 434,977 shares in the last quarter. Cibc World Market Inc. bought a new stake in Dyne Therapeutics during the fourth quarter worth about $1,345,000. Finally, Monashee Investment Management LLC bought a new stake in shares of Dyne Therapeutics during the fourth quarter worth $2,240,000. Institutional investors and hedge funds own 96.68% of the company's stock.

Insiders Place Their Bets

In other news, Director Jason P. Rhodes sold 480,240 shares of the business's stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $22.79, for a total transaction of $10,944,669.60. Following the completion of the sale, the director owned 875,912 shares in the company, valued at $19,962,034.48. The trade was a 35.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Cox sold 3,311 shares of the company's stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total value of $60,789.96. Following the transaction, the chief executive officer directly owned 370,834 shares in the company, valued at $6,808,512.24. The trade was a 0.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders bought 9,000 shares of company stock worth $156,800 and sold 1,558,819 shares worth $34,385,234. Company insiders own 9.46% of the company's stock.

Analyst Ratings Changes

DYN has been the topic of several recent research reports. Morgan Stanley decreased their price target on Dyne Therapeutics from $47.00 to $45.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. Cantor Fitzgerald assumed coverage on Dyne Therapeutics in a research report on Thursday, July 23rd. They set an "overweight" rating for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Evercore set a $33.00 target price on Dyne Therapeutics in a report on Friday, May 15th. Finally, Wall Street Zen cut Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 1st. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Dyne Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $34.42.

Dyne Therapeutics Price Performance

Dyne Therapeutics stock opened at $26.25 on Friday. The stock has a fifty day moving average of $22.00 and a 200-day moving average of $19.18. Dyne Therapeutics, Inc. has a 52 week low of $10.78 and a 52 week high of $27.09. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02. The stock has a market capitalization of $4.90 billion, a P/E ratio of -7.88 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.33). On average, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.37 earnings per share for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source